Retinal amyloid in Alzheimer's disease

Retinal amyloid deposition in Alzheimer's disease patients - Retinal amyloid in Alzheimer's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061190024

Enrollment

Registered

2019-11-25

Start date

2020-01-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease, mild cognitive impairment dementia

Interventions

Curcumin supplement (4g*2days)

D019587

supplement

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Outpatient of the neurology department of our clinic 2. Diagnosed as Alzheimer's disease, mild cognitive impairment(MCI), or normal cognitive function (except for complication of vascular dementia) 3. Native Japanese speaker 4. Age from 65 to 84

Exclusion criteria

Exclusion criteria: 1. Impossible to take crucumin supplement due to severe dysphagia 2. Diagnosed as closed-angle glaucoma, and impossible to use mydriatic agent 3. Severe visual impairment requiring daily support 4. Unable to take curcumin supplement or examination due to severe cognitive decline 5. Judged by researchers not to be eligible

Design outcomes

Primary

Measure	Time frame
retinal amyloid deposition	—

Secondary

Measure	Time frame
1. Background of participants 2. Cognitive function test 3. Brain MRI 4. Cerebral blood flow measured by SPECT 5. Amyloid PET 6. Adverse events 7. Compliance of curcumin	—

Contacts

Public ContactKoh Tadokoro

Okayama University Hospital

p86m6fma@okayama-u.ac.jp+81-86-235-7365

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026